Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
atypical
auditory evoked brainstem potentials
biologic markers
brain biopsy
central vein sign
cerebrospinal fluid, oligoclonal IgG in
disability rating scale, neurological
disability, neurological
gait disorder
L-dopa
MRI
MRI, abnormal
MRI, field strength, high
MRI, susceptibility weighted
multiple sclerosis
multiple sclerosis, diagnosis of
multiple sclerosis, late-onset
multiple sclerosis, prognosis
myelopathy
myelopathy, chronic progressive
neurologic disease, diagnoses of
neuromyelitis optica (Devic's disease)
old age, neurology of
paramagnetic rim lesion, MR
Parkinson disease
Parkinson disease, late onset
Parkinson disease, treatment of
Parkinson disease, young onset
treatment of neurologic disorder
visual evoked response
Showing articles 650 to 700 of 5370 << Previous Next >>

Obsessive-Compulsive Disorder
BMJ 333:424-429, Heyman,I.,et al, 2006

Standardized MR Imaging Protocol for Multiple Sclerosis:Consortium of MS Centers Consensus Guidelines
AJNR 27:455-461, Simon,J.H.,et al, 2006

Significance of T2 Lesions in Multiple Sclerosis: A 13-Year Longitudinal Study
Ann Neurol 60:236-242, Rudick,R.A.,et al, 2006

Does High-Field MR Imaging Have an Influence on the Classification of Patients with Clinically Isolated Syndromes According to Current Diagnostic MR Imaging Criteria for Multiple Sclerosis
AJNR 27:1794-1798, Wattjes,M.P.,et al, 2006

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006

Multiple Sclerosis in Twins From Continental Italy and Sardinia: A Nationwide Study
Ann Neurol 59:27-34, Ristori,G.,et al, 2006

Clinically Isolated Syndromes, A New Oligoclonal Band Test Accurately Predicts Conversion to MS
Neurol 66:576-578, Masjuan,J.,et al, 2006

Metabolic Disease and Stroke: MELAS
emedicine.com, Mandava,P.,et al, 2006

What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006

Multiple Sclerosis - The Plaque and Its Pathogenesis
NEJM 354:942-955, Frohman,E.M.,et al, 2006

Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006

IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006

Gray and White Matter Brain Atrophy and Neuropsychological Impairment in Multiple Sclerosis
Neurol 66:685-692, Sanfilipo,M.P.,et al, 2006

Treatment of Low Back Pain by Acupressure and Physical Therapy: Randomised Controlled Trial
BMJ 332:696-698,680, Hsieh,L.L.-C.,et al, 2006

Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006

Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should be Treated at the Time of Diagnosis
Arch Neurol 63:614-619, Frohman,E.M.,et al, 2006

Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis
Arch Neurol 63:611-619, Pittock,S.J.,et al, 2006

Brain Abnormalities in Neuromyelitis Optica
Arch Neurol 63:390-396, Pittock,S.J.,et al, 2006

Diagnosis and Treatment of Multiple Sclerosis
BMJ 332:525-527, Murray,T.J., 2006

Increase in Multiple Sclerosis Relapse Rate Following in vitro Fertilization
Neurol 66:1280-1281, Laplaud,D.-A.,et al, 2006

Not All Patients With Atrial Fibrillation-Associated Ischemic Stroke Can Be Started on Anticoagulant Therapy
Stroke 37:1217-1220, Somerfield,J.,et al, 2006

Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006

MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006

Multiple Sclerosis: New Insights and Trends
AJNR 27:954-957, Inglese,M., 2006

Past Adult Lead Exposure is Linked to Neurodegeneration Measured by Brain MRI
Neurol 66:1476-1484,1464, Stewart,W.F.,et al, 2006

Revised Diagnostic Criteria for Neuromyelitis Optica
Neurol 66:1485-1489, Wingerchuk,D.M.,et al, 2006

Efficacy and Safety of Intranasal Lorazepam Versus Intramuscular Paraldehyde for Protracted Convulsions in Children: An Open Randomised Trial
Lancet 367:1591-1597,1555, Ahmad,S.,et al, 2006

Accuracy of Magnetic Resonance Imaging for the Diagnosis of Multiple Sclerosis: Systematic Review
BMJ 332:875-878, Whiting P.,et al, 2006

Multiple Sclerosis: The Role of MR Imaging
AJNR 27:1165-1176, Ge,Y., 2006

Tetanus Vaccination and Risk of Multiple Sclerosis: A Systematic Review
Neurol 67:212-215, Hernn,M.A.,et al, 2006

The Clinical Features, MRI Findings, and Outcome of Optic Neuritis in Children
Neurol 67:258-262, Wilejto,M.,et al, 2006

Spinal dural arteriovenous fistulas: a congestive myelopathy that initially mimics a peripheral nerve disorder
Brain 129:3150-3164, Jellema, K., et al, 2006

The Ependymal "Dot-Dash" Sign: An MR Imaging Finding of Early Multiple Sclerosis
AJNR 26:2033-2036, Lisanti, C.J.,et al, 2005

MRI T2 Hypointensity of the Dentate Nucleus is Related to Ambulatory Impairment in Multiple Sclerosis
J Neurol Sci 234:17-24, Tjoa,C.W.,et al, 2005

Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005

Intractable Hiccup and Nausea With Pariaqueductal Lesions in Neuromyelitis Optica
Neurol 65:1479-1482, Misu,T.,et al, 2005

Diffusion MRI in Multiple Sclerosis
Neurol 65:1526-1532, Rovaris,M.,et al, 2005

Axonal Injury in Early Multiple Sclerosis is Irreversible and Independent of the Short-Term Disease Evolution
Neurol 65:1626-1630, Rovaris,M.,et al, 2005

Late-Onset Friedreich Ataxia
Arch Neurol 62:1865-1869, Bhidayasiri,R.,et al, 2005

Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the "McDonald Criteria"
Ann Neurol 58:840-846, Polman,C.H.,et al, 2005

Pregnancy, Delivery, and Birth Outcome in Women with Multiple Sclerosis
Neurol 65:1961-1963, Dahl,J.,et al, 2005

Modafinil for Fatigue in MS
Neurol 64:1139-1143, Stankoff,B.,et al, 2005

Anti-a4 Integrin Therapy for Multiple Sclerosis
Neurol 64:1336-1342, Rice,G.P.A.,et al, 2005

Migraine and Cerebral White Matter Lesions
The Neurologist 11:19-29, Gladstone,J.P. &Dodick,D.W., 2005

Is Optic Neuritis More Benign Than Other First Attacks in Multiple Sclerosis?
Ann Neurol 57:210-215, Tintore, M., et al, 2005

FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005

Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis
Arch Neurol 62:785-792, Schwid,S.R.,et al, 2005

Internuclear Ophthalmoplegia
Arch Neurol 62:714-717, Keane,J.R., 2005

Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis
JAMA 293:2496-2500, Levin,L.I.,et al, 2005



Showing articles 650 to 700 of 5370 << Previous Next >>